Cargando…

Avoidance of Harm From Treatment for ANCA-Associated Vasculitis

Purpose of review With established immunosuppressant treatment regimens for anti-neutrophil cytoplasm antibody-associated vasculitides (AAV), prognosis has significantly improved. The mainstay of treatment still comprises high-dose corticosteroids and cyclophosphamide for severe forms, although ritu...

Descripción completa

Detalles Bibliográficos
Autores principales:	King, Catherine, Harper, Lorraine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Vasculitis (C Pagnoux and M Walsh, Section Editors)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694500/ https://www.ncbi.nlm.nih.gov/pubmed/29201630 http://dx.doi.org/10.1007/s40674-017-0082-y

Ejemplares similares

Daratumumab for the treatment of refractory ANCA-associated vasculitis
por: Ostendorf, Lennard, et al.
Publicado: (2023)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Risk factors for serious infections in ANCA-associated vasculitis
por: Odler, Balazs, et al.
Publicado: (2023)

Immune checkpoint inhibitors as potential triggers for ANCA vasculitis
por: Aqeel, Faten, et al.
Publicado: (2022)

Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
por: Aqeel, Faten, et al.
Publicado: (2023)

The Nasal Microbiome in ANCA-Associated Vasculitis: Picking the Nose for Clues on Disease Pathogenesis
por: Dekkema, G. J., et al.
Publicado: (2021)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
por: Yates, Max, et al.
Publicado: (2017)

T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach
por: Martinez Valenzuela, Laura, et al.
Publicado: (2019)

ANCA-associated renal vasculitis is associated with rurality but not seasonality or deprivation in a complete national cohort study
por: Aiyegbusi, Oshorenua, et al.
Publicado: (2021)

Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
por: Heijl, Caroline, et al.
Publicado: (2017)

Prevalence and risk factors of osteonecrosis of the femoral head in patients with ANCA-associated vasculitis: a multicentre cohort study
por: Mimura, Norihiro, et al.
Publicado: (2023)

Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism
por: Casal Moura, Marta, et al.
Publicado: (2023)

Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening
por: Xu, Tingting, et al.
Publicado: (2022)

Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry
por: Puéchal, Xavier, et al.
Publicado: (2022)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Schirmer, Jan Henrik, et al.
Publicado: (2023)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
por: Sanchez-Alamo, Beatriz, et al.
Publicado: (2023)

Seasonal variations in the onset of positive and negative renal ANCA-associated vasculitis in Spain
por: Draibe, Juliana, et al.
Publicado: (2018)

Is There Still a Role of Plasma Exchange in the Current Management of ANCA-Associated Vasculitides?
por: Toyoda, Task, et al.
Publicado: (2022)

CSF2-dependent monocyte education in the pathogenesis of ANCA-induced glomerulonephritis
por: Rousselle, Anthony, et al.
Publicado: (2022)

ANCA Status or Clinical Phenotype — What Counts More?
por: Windpessl, Martin, et al.
Publicado: (2021)

Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial
por: Romand, Xavier, et al.
Publicado: (2023)

Localized Forms of Vasculitis
por: Martins-Martinho, Joana, et al.
Publicado: (2021)

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
por: Merkel, Peter A., et al.
Publicado: (2017)

Diagnostic significance of antineutrophil cytoplasmic antibody (ANCA) titres: a retrospective case-control study
por: Merindol, Julie, et al.
Publicado: (2023)

Phosphatidylinositol 3‐Kinase δ Deficiency Protects From Antimyeloperoxidase Vasculitis
por: Flórez‐Barrós, Fernanda, et al.
Publicado: (2022)

Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Prendecki, Maria, et al.
Publicado: (2022)

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study
por: Jayne, David, et al.
Publicado: (2019)

Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis—a meta-analysis
por: Kuzuya, Kentaro, et al.
Publicado: (2020)

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2019)

VEXAS Syndrome: A Case Series From a Single‐Center Cohort of Italian Patients With Vasculitis
por: Muratore, Francesco, et al.
Publicado: (2022)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

Vessel inflammation and morphological changes in patients with large vessel vasculitis: a retrospective study
por: Besutti, Giulia, et al.
Publicado: (2022)

Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study
por: Rutherford, Matthew A., et al.
Publicado: (2021)

Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register
por: De Miguel, Eugenio, et al.
Publicado: (2022)

Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis
por: Monti, Sara, et al.
Publicado: (2019)

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis
por: Águeda, Ana F, et al.
Publicado: (2019)

Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: a matched cross-sectional study
por: Besutti, Giulia, et al.
Publicado: (2023)

Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
por: Chrysidis, Stavros, et al.
Publicado: (2018)

Spectrum of Large and Medium Vessel Vasculitis in Adults: Primary Vasculitides, Arthritides, Connective Tissue, and Fibroinflammatory Diseases
por: Seitz, Luca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rnu1i6hqtebtir62po6pck9n2v